MELBORNE, Australia, April 3 (UPI) -- Australian firm ChemGenex said Tuesday it has begun its second phase 2/3 study of Ceflatonin for chronic myeloid leukemia.
The company said it would test the treatment in 50 to 75 patients with CML who have failed or were intolerant to therapy with two or more tyrosine kinase inhibitors -- typically Gleevec or Sprycel.
Patients who fail on these drugs have limited treatment options and the study will assess if ChemGenex's drug might help fill that gap, the company said.
The first patient was enrolled in the CML-203 study at the Houston-based MD Anderson Cancer Center, ChemGenex said, with the study eventually spanning 15 centers in the United States and Europe.
Initial data from the study will be available in the first half of 2008, the company said.
